ArticleAIDS (London, England)2021
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.
Article in AIDS (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Serological response following COVID-19 vaccines in patients living with HIV: a dose-response meta-analysis.Scientific reports · 2023Pooled it
- Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.Journal of virology · 2025Trial
- Characteristics of humoral and T-cell immune responses in people living with HIV after breakthrough SARS-CoV-2 Omicron variant infection during December 2022 to January 2023.Virologica Sinica · 2026Article
- Safety Profile of COVID-19 Vaccines in HIV Patients Undergoing ART and Their Impact on Immune Recovery and HIV Reservoirs.Infectious diseases & immunity · 2024Article
- Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus.Frontiers in immunology · 2024Article
- Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques.Emerging microbes & infections · 2023Article
- Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV.iScience · 2023Article
- Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV.bioRxiv : the preprint server for biology · 2023Article
- Correlation between CD4 T-Cell Counts and Seroconversion among COVID-19 Vaccinated Patients with HIV: A Meta-Analysis.Vaccines · 2023Review
- Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.BMC infectious diseases · 2023Article
- Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study.Frontiers in immunology · 2023Article
- The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study.Frontiers in immunology · 2023Article
- Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Article
- Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand.Emerging infectious diseases · 2022Article
- A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV.Open forum infectious diseases · 2022Review
- Advances in Research on COVID-19 Vaccination for People Living with HIV.Infectious diseases & immunity · 2022Article
- Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals.AIDS research and therapy · 2022Article
- Humoral Immune Response to Inactivated COVID-19 Vaccination at the 3rd Month among People Living with HIV.Research square · 2022Article
- Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies.Open forum infectious diseases · 2022Article
- Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.The lancet. HIV · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
In this study of 12 people with HIV (PWH) who received the first dose of SARS-CoV-2 mRNA vaccination, anti-SARS-CoV-2 receptor-binding domain antibodies were detectable in all participants; lower antibody levels were seen in those with lower CD4+ counts, and vaccine reactions were generally mild.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.